대한핵의학회지 (1967년~2009년)
대한핵의학회지 1986;20(2)85~16
자가면역성 갑상선질환에서 TSH 수용체 항체의 역활에 관한 연구 ( The Roles of the TSH Receptor Antibodies in Autoimmune Thyroid Diseases )
()
Author 고창순(Chang Soon Koh),
Affiliation
Abstract

To evaluate the clinical and pathogenetic roles of TSH receptor antibodies in autoimmune thyroid diseases, TBII were measured by TSH-radioreceptor assay methods in 352 patients with Graves disease, 108 patients with other thyroid diseases and 69 normal persons. The normal range of TBII activity was less than 15%. The frequencies of detectable TBIl in 169 patients with untreated Graves disease, 31 patients with hyperthyroidism under treatment and 70 patients with euthyrodism under treatment were 92.4%, 87.1% and 54.3% respectively. However 12 (21.8%) out af 55 patients who have been in remission more than one year after discontinuation of antithyroid drugs treatment had detectable TBII activities in their sera. In 196 patients with untreated Graves disease, the frequency of TBII increased by increasing size of goiter and the frequency of proptosis was significantly high in patients whose TBII activities were more than 60%. TBll activities were roughly correlated with total TT, and free T, index but low r(2) value(less than 0.1). In 67 patients with Graves disease who were positive TB1I before antithyroid drugs treatment, TBII activities began to decrease from the third months and it was converted to negative in 35.8% of patients at 12 months after treatment. There were no significant differences of the declining and disappearing rates of TBII activities between high dose and conventional dose groups. TBII aotivities were significantly increased initially (2-4 months) and then began to decrease from 5-9 months after 'I treatment. There were two groups, one whose TBII activities decreased gradually and the other did not change untill 12 months after subtotal thyroidectomy. Alkhough preoperative clinical and laboratory findings of both groups were not different, TBII activities of non-decreasing group were significantly higher than those of decreasing group(74.6+18.6% vs 39.2+15.2%; P(0.01). Thirty three(55.9%) out of 59 patients with Graves disease relapsed within 1 year after discontinu- ation of antithyroid drugs. The positive rate of TBII at the end of antithyroid drug treatment in refapse group(n=33) was significantly higher than those in remission group (n=26) (63.6% vs 23,1%; P < 0.05). The mean value of TBII activities at the end of antithyroid drug treatment in relapse group was significantly elevated (29.7+21.4% vs 14.7+11.1%; P<0.05). Positive predictive value of TRII for relapse was 77.8%, which was not different from those of TRH not>responsiveness(78.6%). The frequencies of detectable TBII in 68 patients with EIashimotos thyroiditis, 10 patients with painless thyroiditis and 5 patients subacute thyroiditis were 14.i /o, 20% and 0%, respectively. However in 25 patients with primary nongoitrous myxedema, 1 1 patients(44%) showed TBII activities in their sera. 9 out of ll patients who had TBII activities in their sera showed high TBIl activities(more than 70'/ binding inhibition) and their IgG concentrations showing 50% binding inhibition of 125I-bTSH to the TSH receptor were ranges of 0.1 2.6 mg/dl. One patierrt who had high titer of TBII in her serum delivered a hypothyroid baby due to transplacental transfer of maternal TBII. These findings suggested that 1) TSH receptor antibodies are closely related to a pathogenetic factor of Graves hyperthyroidism and of some patients with primary non-goitrous myxedema, 2) measurement of TSH receptor antibodies is helpful m evaluating the clinical outcome of patients with Graves disease during antithyroid drug treatment and in predicting the neonatal transient hypothyr- oidism of baby delivered from primary myxedema patients. 3) there are 2 or more different types of TSH receptor antibodies in autoimmune thyroid diseases including one which stimulates thyroid by binding to the TSH receptor and another which blocks adenylate cyclase stimulation by TSH.

Keyword
Full text Article 28500683.pdf 28500683.pdf
(03121)서울시 종로구 지봉로 29 금호팔레스빌딩 1705호
TEL : 02-745-2040 FAX : 02-745-3833 E-mail : ksnm@ksnm.or.kr
Copyright 2012 by The Korean Society of Nuclear Medicine(KSNM)